Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | TP53 | P04637 | 5/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.80 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | TNKS | O95271 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | SULT2A1 | Q06520 | 1/20 | 0.60 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.60 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11920016 | 0.92 | TP53 (0.84) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL11920018 | 0.89 | TP53 (1.00) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL11919957 | 0.80 | TP53 (0.69) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL16010756 | 0.79 | TNKS2 (1.00) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL11919905 | 0.77 | NPSR1 (0.77) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL13046998 | 0.77 | NPSR1 (0.90) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL11919901 | 0.77 | TP53 (1.00) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL11919942 | 0.75 | LMNA (0.78) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL11919979 | 0.75 | NPSR1 (0.87) | MAPTTP53SMN1; SMN2TNKS2NPSR1 | |
| SCHEMBL11919898 | 0.75 | TNKS2 (1.00) | MAPTTP53SMN1; SMN2TNKS2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-08-16 | — | — | US | disclosed |
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | WNT1, AXIN2, WNT3 | MAPT 2763/4885TP53 53/4885SMN1; SMN2 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.